sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Patients receiving flurbiprofen and furosemide or other diuretics should be observed closely to determine if the desired effect is obtained.
|
flurbiprofen
|
furosemide
|
ADVISE
|
Flurbiprofen_ddi.xml
|
DDI-DrugBank.d529.s17
|
DDI-DrugBank.d529.s17.p0
|
Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
|
Beta-blockers
|
insulin
|
EFFECT
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s3
|
DDI-DrugBank.d313.s3.p3
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
indomethacin
|
Aleve
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p263
|
Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.
|
BREVIBLOC
|
digoxin
|
ADVISE
|
Esmolol_ddi.xml
|
DDI-DrugBank.d422.s10
|
DDI-DrugBank.d422.s10.p0
|
Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
|
tricyclic antidepressants
|
clonidine
|
EFFECT
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s4
|
DDI-DrugBank.d238.s4.p1
|
Similarly, the effects of phenytoin on phenobarbital, valproic acid and sodium plasma valproate concentrations are unpredictable
|
phenytoin
|
phenobarbital
|
EFFECT
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s15
|
DDI-DrugBank.d40.s15.p0
|
Theophylline: Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.
|
Theophylline
|
theophylline
|
NONE
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s6
|
DDI-DrugBank.d78.s6.p1
|
The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, iron or zinc supplements.
|
lymecycline
|
iron
|
MECHANISM
|
Lymecycline_ddi.xml
|
DDI-DrugBank.d79.s0
|
DDI-DrugBank.d79.s0.p0
|
These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.
|
erythromycin
|
fexofenadine
|
MECHANISM
|
Fexofenadine_ddi.xml
|
DDI-DrugBank.d466.s17
|
DDI-DrugBank.d466.s17.p2
|
Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.
|
pyrilamine
|
phenyltoloxamine
|
NONE
|
2578597.xml
|
DDI-MedLine.d57.s2
|
DDI-MedLine.d57.s2.p18
|
Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.
|
Clozapine
|
fluvoxamine
|
ADVISE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s23
|
DDI-DrugBank.d480.s23.p0
|
Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.
|
alprazolam
|
fluvoxamine
|
MECHANISM
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s12
|
DDI-DrugBank.d76.s12.p11
|
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
|
ALFENTA
|
CNS depressants
|
EFFECT
|
Alfentanil_ddi.xml
|
DDI-DrugBank.d8.s0
|
DDI-DrugBank.d8.s0.p0
|
In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.
|
cimetidine
|
flecainide
|
MECHANISM
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s14
|
DDI-DrugBank.d87.s14.p0
|
The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
|
benzodiazepines
|
monoamine oxidase inhibitors
|
EFFECT
|
Clorazepate_ddi.xml
|
DDI-DrugBank.d335.s3
|
DDI-DrugBank.d335.s3.p3
|
Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.
|
atorvastatin
|
CRIXIVAN
|
ADVISE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s72
|
DDI-DrugBank.d97.s72.p4
|
In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.
|
digoxin
|
ertapenem
|
NONE
|
Ertapenem_ddi.xml
|
DDI-DrugBank.d329.s4
|
DDI-DrugBank.d329.s4.p4
|
It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.
|
Vardenafil
|
erythromycin
|
ADVISE
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s6
|
DDI-DrugBank.d198.s6.p0
|
Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.
|
BUSULFEX
|
phenytoin
|
MECHANISM
|
Busulfan_ddi.xml
|
DDI-DrugBank.d72.s3
|
DDI-DrugBank.d72.s3.p0
|
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.
|
sulfonylureas
|
probenecid
|
EFFECT
|
Glibenclamide_ddi.xml
|
DDI-DrugBank.d178.s0
|
DDI-DrugBank.d178.s0.p4
|
Rifampin and warfarin: a drug interaction.
|
Rifampin
|
warfarin
|
INT
|
1115445.xml
|
DDI-MedLine.d116.s0
|
DDI-MedLine.d116.s0.p0
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
AKINETON
|
meperidine
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p10
|
The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either alcohol or acamprosate.
|
Acamprosate
|
alcohol
|
NONE
|
Acamprosate_ddi.xml
|
DDI-DrugBank.d0.s0
|
DDI-DrugBank.d0.s0.p3
|
Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).
|
rifampin
|
Gleevec
|
MECHANISM
|
Imatinib_ddi.xml
|
DDI-DrugBank.d115.s6
|
DDI-DrugBank.d115.s6.p0
|
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
|
non-steroidal anti-inflammatory drugs
|
hydrochloroquine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s90
|
DDI-DrugBank.d64.s90.p14
|
Opioids are strong central nervous system depressants, but regular users develop physiological tolerance allowing gradually increased dosages.
|
Opioids
|
central nervous system depressants
|
NONE
|
Heroin_ddi.xml
|
DDI-DrugBank.d514.s0
|
DDI-DrugBank.d514.s0.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
miconazole
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p29
|
Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.
|
phenobarbital
|
progestins
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s12
|
DDI-DrugBank.d485.s12.p21
|
Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.
|
etodolac
|
phenylbutazone
|
ADVISE
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s20
|
DDI-DrugBank.d219.s20.p0
|
These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, sali-cylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone.
|
anticoagulants
|
sulfinpyrazone
|
NONE
|
Enoxaparin_ddi.xml
|
DDI-DrugBank.d474.s1
|
DDI-DrugBank.d474.s1.p5
|
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
|
rifampin
|
corticosteroids
|
MECHANISM
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s1
|
DDI-DrugBank.d487.s1.p7
|
In uninfected volunteers, 46% developed rash while receiving SUSTIVA and clarithromycin.
|
SUSTIVA
|
clarithromycin
|
EFFECT
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s29
|
DDI-DrugBank.d531.s29.p0
|
Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.
|
digoxin
|
hydralazine
|
NONE
|
Benazepril_ddi.xml
|
DDI-DrugBank.d561.s11
|
DDI-DrugBank.d561.s11.p14
|
Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
|
furosemide
|
hydroxyurea
|
NONE
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s2
|
DDI-DrugBank.d75.s2.p20
|
In a study of schizophrenic patients who received clozapine under steady state conditions, fluvoxamine or paroxetine was added in 16 and 14 patients, respectively.
|
clozapine
|
paroxetine
|
NONE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s19
|
DDI-DrugBank.d480.s19.p1
|
Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.
|
phenobarbital
|
quinidine
|
NONE
|
11206047.xml
|
DDI-MedLine.d111.s2
|
DDI-MedLine.d111.s2.p9
|
Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
|
ciprofloxacin
|
cyclosporine
|
EFFECT
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s2
|
DDI-DrugBank.d123.s2.p2
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
ampicillin
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p3
|
If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.
|
chlorprothixene
|
opioids
|
EFFECT
|
Chlorprothixene_ddi.xml
|
DDI-DrugBank.d503.s2
|
DDI-DrugBank.d503.s2.p9
|
Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;
|
Amphetamines
|
phenytoin
|
MECHANISM
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s25
|
DDI-DrugBank.d236.s25.p2
|
The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol;
|
CMI
|
haloperidol
|
MECHANISM
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s5
|
DDI-DrugBank.d238.s5.p0
|
Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and digitoxin.
|
digoxin
|
digitoxin
|
NONE
|
Colestipol_ddi.xml
|
DDI-DrugBank.d345.s14
|
DDI-DrugBank.d345.s14.p5
|
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and Abciximab) may increase the risk of bleeding if administered prior to, during, or after Activase therapy.
|
vitamin K antagonists
|
Activase
|
EFFECT
|
Alteplase_ddi.xml
|
DDI-DrugBank.d508.s1
|
DDI-DrugBank.d508.s1.p8
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
delavirdine
|
desipramine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p440
|
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
|
phenothiazines
|
quinidine
|
NONE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s30
|
DDI-DrugBank.d480.s30.p20
|
Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.
|
Vardenafil
|
indinavir
|
ADVISE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s93
|
DDI-DrugBank.d97.s93.p0
|
Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.
|
sirolimus
|
diltiazem
|
ADVISE
|
11180036.xml
|
DDI-MedLine.d86.s9
|
DDI-MedLine.d86.s9.p0
|
Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids may cause hypokalemia.
|
ethoxzolamide
|
diuretics
|
EFFECT
|
Ethoxzolamide_ddi.xml
|
DDI-DrugBank.d286.s2
|
DDI-DrugBank.d286.s2.p0
|
Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.
|
beta-adrenergic blocking agents
|
calcium antagonist
|
EFFECT
|
Betaxolol_ddi.xml
|
DDI-DrugBank.d489.s6
|
DDI-DrugBank.d489.s6.p0
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
oxaprozin
|
naproxen
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p286
|
Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.
|
lithium
|
CELEBREX
|
MECHANISM
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s19
|
DDI-DrugBank.d172.s19.p7
|
If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
|
desipramine hydrochloride
|
psychotropic agents
|
EFFECT
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s23
|
DDI-DrugBank.d386.s23.p0
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
carbamazepine
|
saquinavir
|
MECHANISM
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p125
|
d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;
|
d-amphetamine
|
desipramine
|
MECHANISM
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s4
|
DDI-DrugBank.d158.s4.p0
|
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
|
phenytoin
|
corticosteroid
|
ADVISE
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s1
|
DDI-DrugBank.d487.s1.p6
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
meprobamate
|
rifampin
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p252
|
Lotensin has been used concomitantly with beta-adrenergic-blocking agents, calcium-channel-blocking agents, diuretics, digoxin, and hydralazine, without evidence of clinically important adverse interactions.
|
beta-adrenergic-blocking agents
|
diuretics
|
NONE
|
Benazepril_ddi.xml
|
DDI-DrugBank.d561.s11
|
DDI-DrugBank.d561.s11.p6
|
In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values.
|
TAMBOCOR
|
propranolol
|
MECHANISM
|
Flecainide_ddi.xml
|
DDI-DrugBank.d87.s3
|
DDI-DrugBank.d87.s3.p0
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
sodium colistemethate
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p23
|
Cholestyramine: Cholestyramine binds both T4 and T3 in the intestine, thus impairing absorption of these thyroid hormones.
|
Cholestyramine
|
T4
|
MECHANISM
|
Liothyronine_ddi.xml
|
DDI-DrugBank.d54.s8
|
DDI-DrugBank.d54.s8.p4
|
Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.
|
warfarin
|
enoxacin
|
ADVISE
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s25
|
DDI-DrugBank.d395.s25.p0
|
Paroxetine: Coadministration of a single dose of Sonata 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.
|
Paroxetine
|
paroxetine
|
NONE
|
Zaleplon_ddi.xml
|
DDI-DrugBank.d324.s6
|
DDI-DrugBank.d324.s6.p1
|
Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
|
clonidine
|
insulin
|
EFFECT
|
Insulin Glargine recombinant_ddi.xml
|
DDI-DrugBank.d527.s3
|
DDI-DrugBank.d527.s3.p6
|
ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.
|
anesthetics
|
sympathomimetic amines
|
NONE
|
Isoproterenol_ddi.xml
|
DDI-DrugBank.d55.s2
|
DDI-DrugBank.d55.s2.p4
|
A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.
|
phenytoin
|
coumarin anticoagulant
|
NONE
|
Ethotoin_ddi.xml
|
DDI-DrugBank.d359.s2
|
DDI-DrugBank.d359.s2.p2
|
Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
Protease Inhibitors
|
cisapride
|
NONE
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s12
|
DDI-DrugBank.d237.s12.p2
|
- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.
|
Probenecid
|
probenecid
|
NONE
|
Bumetanide_ddi.xml
|
DDI-DrugBank.d331.s4
|
DDI-DrugBank.d331.s4.p0
|
Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.
|
STRATTERA
|
albuterol
|
ADVISE
|
Atomoxetine_ddi.xml
|
DDI-DrugBank.d11.s0
|
DDI-DrugBank.d11.s0.p4
|
Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.
|
heroin
|
Valium
|
EFFECT
|
Heroin_ddi.xml
|
DDI-DrugBank.d514.s2
|
DDI-DrugBank.d514.s2.p4
|
Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
|
tetracyclines
|
anticoagulant
|
ADVISE
|
Demeclocycline_ddi.xml
|
DDI-DrugBank.d409.s0
|
DDI-DrugBank.d409.s0.p0
|
Oral neomycin sulfate may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.
|
neomycin sulfate
|
coumarin
|
EFFECT
|
Neomycin_ddi.xml
|
DDI-DrugBank.d330.s5
|
DDI-DrugBank.d330.s5.p0
|
Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.
|
Theophylline
|
theophylline
|
NONE
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s16
|
DDI-DrugBank.d123.s16.p3
|
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.
|
propoxyphene
|
sulfonamide antibiotics
|
NONE
|
Insulin recombinant_ddi.xml
|
DDI-DrugBank.d313.s1
|
DDI-DrugBank.d313.s1.p48
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
Probenecid
|
bumetanide
|
MECHANISM
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p21
|
Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.
|
carbamazepine
|
aripiprazole
|
MECHANISM
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s7
|
DDI-DrugBank.d509.s7.p0
|
RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d.
|
fluvoxamine
|
tolbutamide
|
MECHANISM
|
11180037.xml
|
DDI-MedLine.d99.s9
|
DDI-MedLine.d99.s9.p0
|
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;
|
phenobarbital
|
rifampin
|
NONE
|
Levobupivacaine_ddi.xml
|
DDI-DrugBank.d320.s3
|
DDI-DrugBank.d320.s3.p7
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
AKINETON
|
antipsychotics
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p12
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
bromelains
|
warfarin sodium
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p403
|
The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
|
alprazolam
|
ethanol
|
EFFECT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s0
|
DDI-DrugBank.d131.s0.p8
|
Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.
|
propoxyphene
|
alprazolam
|
MECHANISM
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s6
|
DDI-DrugBank.d131.s6.p0
|
Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin.
|
diazepam
|
metamizol
|
EFFECT
|
11210678.xml
|
DDI-MedLine.d67.s6
|
DDI-MedLine.d67.s6.p0
|
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
|
Mefloquine
|
anti-arrhythmic
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s9
|
DDI-DrugBank.d220.s9.p0
|
Interaction of clindamycin and gentamicin in vitro.
|
clindamycin
|
gentamicin
|
INT
|
15825309.xml
|
DDI-MedLine.d49.s0
|
DDI-MedLine.d49.s0.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
diazepam
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p12
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
diflunisal
|
pyrazolones
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p805
|
Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.
|
protease inhibitor
|
saquinavir
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s18
|
DDI-DrugBank.d124.s18.p5
|
Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressants when cimetidine is added to the drug regimen.
|
tricyclic antidepressants
|
cimetidine
|
EFFECT
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s1
|
DDI-DrugBank.d202.s1.p0
|
Binding to plasma protein is not significantly altered by diazepam, diphenylhydantoin, or phenylbutazone.
|
diazepam
|
phenylbutazone
|
NONE
|
Dantrolene_ddi.xml
|
DDI-DrugBank.d305.s2
|
DDI-DrugBank.d305.s2.p1
|
Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with furosemide and ACE inhibitors.
|
NSAIDs
|
ACE inhibitors
|
INT
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s7
|
DDI-DrugBank.d172.s7.p4
|
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
|
alprazolam
|
clarithromycin
|
NONE
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s8
|
DDI-DrugBank.d131.s8.p62
|
Methotrexate: Ibuprofen, as well as other nonsteroidal anti-inflammatory drugs, probably reduces the tubular secretion of methotrexate based on in vitro studies in rabbit kidney slices.
|
Ibuprofen
|
methotrexate
|
MECHANISM
|
Ibuprofen_ddi.xml
|
DDI-DrugBank.d415.s5
|
DDI-DrugBank.d415.s5.p4
|
Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.
|
astemizole
|
ketoconazole
|
ADVISE
|
Ketoconazole_ddi.xml
|
DDI-DrugBank.d458.s6
|
DDI-DrugBank.d458.s6.p0
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
metoclopramide
|
sulfonylureas
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p514
|
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or amoxicillin.
|
phenytoin
|
clarithromycin
|
NONE
|
Esomeprazole_ddi.xml
|
DDI-DrugBank.d29.s3
|
DDI-DrugBank.d29.s3.p7
|
Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).
|
aspirin
|
ginkgo
|
NONE
|
Icosapent_ddi.xml
|
DDI-DrugBank.d35.s0
|
DDI-DrugBank.d35.s0.p5
|
Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.
|
ranitidine
|
IRESSA
|
MECHANISM
|
Gefitinib_ddi.xml
|
DDI-DrugBank.d207.s7
|
DDI-DrugBank.d207.s7.p4
|
[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.
|
pyreneperone
|
3H-spiroperidol
|
NONE
|
2857100.xml
|
DDI-MedLine.d15.s0
|
DDI-MedLine.d15.s0.p28
|
Prolonged recovery time may occur if barbiturates and/or narcotics are used concurrently with ketamine.
|
barbiturates
|
ketamine
|
EFFECT
|
Ketamine_ddi.xml
|
DDI-DrugBank.d518.s0
|
DDI-DrugBank.d518.s0.p1
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
bupropion
|
Type 1C antiarrhythmics
|
ADVISE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p13
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.